Topical Mitomycin C is indicated in the treatment of which of the follwoing conditions?: (A) Endoscopic treatment of angiofibroma, (B) Treatment of skull base osteomyelitis, (C) Sturge Weber syndrome, (D) Treatment for laryngeal stenosis
Answer is D. Topical application of Mitomycin C after endoscopic dilatation of laryngotracheal stenosis prevents restenosis. Mitomycin-C (MMC) inhibits fibroblast proliferation and synthesis of extracellular matrix proteins, and thereby modulates wound healing and scarring.